HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE

Objective: To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files of patients with malignant CNS tumors between 1987-2020 were analyzed retrospectively. There were 44 patients with HGG. Case report: Diagnosis of patients as follows:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nur OLGUN, Deniz KIZMAZOGLU, Dilek INCE, Emre CECEN, Şefika AKYOL, Ayşe ONAL, Batuhan OZDOGAR, Ceren KIZMAZOGLU, Ayşe DEMIRAL, Rıza CETINGOZ, Handan UCAR, Erdener OZER
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/6223bbd81eb14c43a6753a4d27825dd3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6223bbd81eb14c43a6753a4d27825dd3
record_format	dspace
spelling	oai:doaj.org-article:6223bbd81eb14c43a6753a4d27825dd32021-11-10T04:39:05ZHIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE2531-137910.1016/j.htct.2021.10.1093https://doaj.org/article/6223bbd81eb14c43a6753a4d27825dd32021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012402https://doaj.org/toc/2531-1379Objective: To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files of patients with malignant CNS tumors between 1987-2020 were analyzed retrospectively. There were 44 patients with HGG. Case report: Diagnosis of patients as follows: 21 pons glioma, 2 anaplastic astrocytoma, 11 anaplastic ependimoma, 7 glioblastoma multiforme, 1 glioblastoma, 2 gliomatosis cerebri. The median age at diagnosis was 6,5 yrs (7 – 17 yrs), M/F:25/19. Age distribution: <5 yrs 12 patients, 5-10 yrs 18 patients, 10-18 yrs 14 patients. The most frequent complaints for pons gliomas: cranial nerve paralysis (52%), visual impairment (48%), headache (38%), power loss (43%) and speech disorder (30%). Methodology: Surgery was performed to extrinsic component of mass in 3 patients of pons gliomas.For other HGG: 7 subtotal resection and 16 gross total resection had performed.7 patients died before RT. And other 37 patients received radiotherapy. RT total doses varied between 50-60 Gy.7 patients were not received chemotherapy, 3 of them died before chemo, and others received only RT. For other HGGs, platin based regimens used for the first line treatment. Temozolamide, bevacizumab, irinotecan as the other options. Results: Median progression free survival time was 6 mos (2weeks-25 mos) for pons gliomas, for other gliomas median progression free survival time was 14 mos(0 -74 mos).For pons gliomas: Event free survival rate for 6 mos was 75%, for one year 17%;one year, 18 mos, and two years overall survival rates were 84%,52% and 10%respectively.For other HGGs: Event free survival rate for one year and two years were 57% and 17% respectively. One year and two years overall survival rates were 73% and 36% respectively. Conclusion: High grade glioma is a group of tumors in which still the helplessness experienced in treatment. Despite radiotherapy and chemotherapy, prognosis is very poor. The progression free and overall survival rates of patients were similar to literature. With new developments in molecular pathology, as the use of molecular target therapies, the progression free survival rates newly will improve.Nur OLGUNDeniz KIZMAZOGLUDilek INCEEmre CECENŞefika AKYOLAyşe ONALBatuhan OZDOGARCeren KIZMAZOGLUAyşe DEMIRALRıza CETINGOZHandan UCARErdener OZERElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S63-S64 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Nur OLGUN Deniz KIZMAZOGLU Dilek INCE Emre CECEN Şefika AKYOL Ayşe ONAL Batuhan OZDOGAR Ceren KIZMAZOGLU Ayşe DEMIRAL Rıza CETINGOZ Handan UCAR Erdener OZER HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
description	Objective: To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files of patients with malignant CNS tumors between 1987-2020 were analyzed retrospectively. There were 44 patients with HGG. Case report: Diagnosis of patients as follows: 21 pons glioma, 2 anaplastic astrocytoma, 11 anaplastic ependimoma, 7 glioblastoma multiforme, 1 glioblastoma, 2 gliomatosis cerebri. The median age at diagnosis was 6,5 yrs (7 – 17 yrs), M/F:25/19. Age distribution: <5 yrs 12 patients, 5-10 yrs 18 patients, 10-18 yrs 14 patients. The most frequent complaints for pons gliomas: cranial nerve paralysis (52%), visual impairment (48%), headache (38%), power loss (43%) and speech disorder (30%). Methodology: Surgery was performed to extrinsic component of mass in 3 patients of pons gliomas.For other HGG: 7 subtotal resection and 16 gross total resection had performed.7 patients died before RT. And other 37 patients received radiotherapy. RT total doses varied between 50-60 Gy.7 patients were not received chemotherapy, 3 of them died before chemo, and others received only RT. For other HGGs, platin based regimens used for the first line treatment. Temozolamide, bevacizumab, irinotecan as the other options. Results: Median progression free survival time was 6 mos (2weeks-25 mos) for pons gliomas, for other gliomas median progression free survival time was 14 mos(0 -74 mos).For pons gliomas: Event free survival rate for 6 mos was 75%, for one year 17%;one year, 18 mos, and two years overall survival rates were 84%,52% and 10%respectively.For other HGGs: Event free survival rate for one year and two years were 57% and 17% respectively. One year and two years overall survival rates were 73% and 36% respectively. Conclusion: High grade glioma is a group of tumors in which still the helplessness experienced in treatment. Despite radiotherapy and chemotherapy, prognosis is very poor. The progression free and overall survival rates of patients were similar to literature. With new developments in molecular pathology, as the use of molecular target therapies, the progression free survival rates newly will improve.
format	article
author	Nur OLGUN Deniz KIZMAZOGLU Dilek INCE Emre CECEN Şefika AKYOL Ayşe ONAL Batuhan OZDOGAR Ceren KIZMAZOGLU Ayşe DEMIRAL Rıza CETINGOZ Handan UCAR Erdener OZER
author_facet	Nur OLGUN Deniz KIZMAZOGLU Dilek INCE Emre CECEN Şefika AKYOL Ayşe ONAL Batuhan OZDOGAR Ceren KIZMAZOGLU Ayşe DEMIRAL Rıza CETINGOZ Handan UCAR Erdener OZER
author_sort	Nur OLGUN
title	HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
title_short	HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
title_full	HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
title_fullStr	HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
title_full_unstemmed	HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
title_sort	high grade glioma of central nervous system: single center treatment experience
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6223bbd81eb14c43a6753a4d27825dd3
work_keys_str_mv	AT nurolgun highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT denizkizmazoglu highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT dilekince highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT emrececen highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT sefikaakyol highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT ayseonal highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT batuhanozdogar highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT cerenkizmazoglu highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT aysedemiral highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT rızacetingoz highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT handanucar highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience AT erdenerozer highgradegliomaofcentralnervoussystemsinglecentertreatmentexperience
_version_	1718440561987289088

HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE

Ejemplares similares